Advances in the development of therapeutic strategies against COVID-19 and perspectives in the drug design for emerging SARS-CoV-2 variants

Yin, Jialing; Li, Chengcheng; Ye, Chunhong; Ruan, Zhihui; Liang, Yicong; Li, Yongkui; Wu, Jianguo; Luo, Zhen

doi:10.1016/j.csbj.2022.01.026

Cited by 56 publications

(37 citation statements)

References 192 publications

(186 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The knowledge of COVID-19 has increased greatly with the in-depth study, which give a boost to the continuous development of candidate drugs in COVID-19 treatment. For instance, several original findings on the pathogenesis of COVID-19 reported by Chinese researchers indicated that some inhibitors of signaling pathways may also be used in combating SARS-CoV-2 125 , 126 , 127 , 128 . It was reported that SARS-CoV-2 N protein is a key mediator for acute kidney injury (AKI), which can induce AKI via the Smad3-dependent G1 cell cycle arrest mechanism 127 .…”

Section: Discussionmentioning

confidence: 99%

Research and development of Chinese anti-COVID-19 drugs

Meng

Zhu

et al. 2022

Acta Pharmaceutica Sinica B

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Research and development of Chinese anti-COVID-19 drugs

Meng

Zhu

et al. 2022

Acta Pharmaceutica Sinica B

View full text Add to dashboard Cite

“…The drug is approved in many countries for RA, Castleman’s disease and juvenile idiopathic arthritis, and is also expected to have therapeutic effects on giant cell arteritis, polymyalgia rheumatica, and large-vessel vasculitis [ 48 ]. Tocilizumab was also approved for severe COVID-19 treatment by the EMA in 2021 [ 49 ].…”

Section: Tocilizumabmentioning

confidence: 99%

New Era in Systemic Sclerosis Treatment: Recently Approved Therapeutics

Ebata

Yoshizaki‐Ogawa²,

Sato³

et al. 2022

JCM

View full text Add to dashboard Cite

Systemic sclerosis (SSc) is a chronic autoimmune disease with a poor prognosis. Among the various complications of SSc, treatment options for the fibrotic lesions, skin sclerosis, and SSc-associated interstitial lung disease (SSc-ILD) have been limited. However, since 2019, the efficacy and safety of nintedanib, tocilizumab, and rituximab for SSc or SSc-ILD have been demonstrated in double-blind, randomized, placebo-controlled trials, respectively. The antifibrotic agent nintedanib was approved for SSc-ILD in all regions of the United States, Europe, and Japan after the SENSCIS study confirmed that it suppressed the reduction in forced vital capacity (FVC), a measure of SSc-ILD. Tocilizumab, an anti-interleukin-6 receptor antibody, was approved for the treatment of SSc-ILD in the United States after the FocuSSced study showed that it inhibited the decrease in FVC. Rituximab, an anti-CD20 antibody, showed improvement in both modified Rodnan skin score, a measure of skin sclerosis, and FVC in the DESIRES study, and was approved in Japan for the treatment of SSc itself. With the development of these three drugs, SSc treatment is entering a new era. This paper outlines the latest advances in SSc therapeutics, focusing on nintedanib, tocilizumab, and rituximab.

show abstract

“…In cells with high transmembrane protease serines 2 (TMPRSS2) expression (e.g. Calu-3, a human Lung Cancer Cell Line which is with high TMPRSS2 expression but deficiency in cathepsin L), SARS-CoV-2 enter into cells by membrane fusion-mediated infection after TMPRSS2 cleaves S protein into S1 and S2 subunits ( 54 , 55 ), and binds with S2 subunit ( 55 , 56 ). In cells with low TMPRSS2 expression (e.g.…”

Section: Sars-cov-2 Rna Positive In Breastmilk But Without Infectious...mentioning

confidence: 99%

“…In cells with low TMPRSS2 expression (e.g. Vero E6, an African green monkey kidney cell line), SARS-CoV-2 enters into cells via the endocytosis route to form endosome, and SARS-CoV-2 genomic RNA are released from endosome into cytoplasm directly with the assistance of cathepsin L (CTSL) ( 55 , 56 ) ( Figure 1 ). And in human primary lung epithelial cells or human colorectal adenocarcinoma epithelial cell line Caco-2, both routes are utilized for SARS-CoV-2 entry ( 57 – 59 ).…”

Section: Sars-cov-2 Rna Positive In Breastmilk But Without Infectious...mentioning

confidence: 99%

Overview of Breastfeeding Under COVID-19 Pandemic

Pang

Tian

et al. 2022

Front. Immunol.

View full text Add to dashboard Cite

During the global pandemic of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), pregnant and lactating women are at higher risk of infection. The potential of viral intrauterine transmission and vertical transmission by breastfeeding has raised wide concerns. Breastmilk is rich in nutrients that contribute to infant growth and development, and reduce the incidence rate of infant illness and death, as well as inhibit pathogens significantly, and protect infants from infection. Although it is controversial whether mothers infected with COVID-19 should continue to breastfeed, many countries and international organizations have provided recommendations and guidance for breastfeeding. This review presents the risks and benefits of breastfeeding for mothers infected with COVID-19, and the reasons for the absence of SARS-CoV-2 active virus in human milk. In addition, the antiviral mechanisms of nutrients in breastmilk, the levels of SARS-CoV-2 specific antibodies in breastmilk from COVID-19 infected mothers and vaccinated mothers are also summarized and discussed, aiming to provide some support and recommendations for both lactating mothers and infants to better deal with the COVID-19 pandemic.

show abstract

Advances in the development of therapeutic strategies against COVID-19 and perspectives in the drug design for emerging SARS-CoV-2 variants

Cited by 56 publications

References 192 publications

Research and development of Chinese anti-COVID-19 drugs

Research and development of Chinese anti-COVID-19 drugs

New Era in Systemic Sclerosis Treatment: Recently Approved Therapeutics

Overview of Breastfeeding Under COVID-19 Pandemic

Contact Info

Product

Resources

About